Go back to /resources
Back
Position Statements
CRA Position Statement on Safety of Hydroxychloroquine in the Treatment of Rheumatic Diseases
March 23, 2025
The antimalarial drugs, chloroquine and especially hydroxychloroquine (HCQ), are essential drugs in the treatment of rheumatic diseases...
Related Resources
View All
Position Statements
Canadian Rheumatology Association Position Statement on Criteria for Access to Targeted Agents for Rheumatoid Arthritis in Canada
There are currently significant discrepancies between Canadian provinces and territories in the criteria for access to advanced targeted agents for rheumatoid arthritis (RA) treatment. Such targeted agents include biologic medications as well as small molecule inhibitors. In hopes of supporting […]
March 30, 2026
Position Statements
Canadian Rheumatology Association Position Statement for Vaccinations in Patients with Rheumatic Diseases
This new position statement replaces the Canadian Rheumatology Association Position Statement on COVID-19 Vaccination (latest update published March 2022), and advocates for government coverage for vaccines not currently funded for rheumatology patients.
February 18, 2026
Position Statements
Canadian Rheumatology Association Position Statement on Hydroxychloroquine Monitoring Guidance for Optical Coherence Tomography
The antimalarial drugs, hydroxychloroquine (HCQ) and rarely chloroquine, are essential drugs in the treatment of rheumatic diseases. HCQ is currently the only anti-malarial drug available in Canada for the treatment of rheumatic diseases...
December 1, 2025